Abbvie-Genmab’s EPKINLY, the first CD20XCD3 Bispecific Antibody gets US approval for Relapsed/Refractory DLBCL treatment. Roche’s Glofitamab is expected to garner benefits in Europe first. Let's have a glimpse of evolving DLBCL treatment landscape in Relapsed/Refractory setting and if bi-specific as a class can be a threat to CAR-Ts, which already have a strong presence in this setting.
On May 19, 2023, the US FDA approved EPKINLY (epcoritamab-bysp), as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with R/R DLBCL, not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B–cell ...
